Pharmaceutical News RSS Feed - Pharmaceutical News

Study: High-dose prescribing increases by 23% in Canada

Study: High-dose prescribing increases by 23% in Canada

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new research. [More]
Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough. [More]
People who take antidepressants are twice as likely to have dental implants fail

People who take antidepressants are twice as likely to have dental implants fail

A team from McGill University has discovered that people who take the most common antidepressants (such as Celexa, Paxil, Lexapro, Prozac, and Zoloft, the Selective Serotonin Reuptake Inhibitors or SSRIs) are twice as likely to have dental implants fail as those who are not taking SSRIs. [More]
ChromaDex signs NIAGEN supply agreement with Healthy Directions

ChromaDex signs NIAGEN supply agreement with Healthy Directions

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has entered into an ingredient supply agreement with Healthy Directions, a direct-to-consumer nutritional supplement retailer and wholly-owned subsidiary of Helen of Troy Limited. [More]
AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

The ovarian cancer market is highly active with several promising candidates having reached the late stages of development. Three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in mutated [BRCA-deficient] cancer cells, have been identified by Datamonitor Healthcare as front runners. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

The Centers for Disease Control and Prevention (CDC) and Premier, Inc. have released new research on the widespread use of unnecessary and duplicative antibiotics in U.S. hospitals, which could have led to an estimated $163 million in excess costs. [More]
New research shows statins could reduce common diabetes complications

New research shows statins could reduce common diabetes complications

The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinology. [More]
Merck's Keytruda gets FDA approval for treatment of malignant melanoma

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma. [More]
Now, women experiencing morning sickness can benefit from Diclegis drug

Now, women experiencing morning sickness can benefit from Diclegis drug

Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness. [More]
Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. [More]
Pharmaceuticals against malaria can now be produced from waste of plant-extraction

Pharmaceuticals against malaria can now be produced from waste of plant-extraction

Research success through collaborative efforts of chemists and engineers from Berlin/Potsdam and Magdeburg. All of the best currently available pharmaceuticals against malaria can now be produced in pure form using a single process, even from the waste of the plant-extraction. [More]
Researchers examine whether new drug offers added benefit for patients with chronic HCV

Researchers examine whether new drug offers added benefit for patients with chronic HCV

The drug simeprevir has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection. [More]
New discovery could help efforts to produce more effective vaccines

New discovery could help efforts to produce more effective vaccines

The best defense is a good offense, especially when it comes to the immune system. The troops that respond to an infection are split into two squadrons, and, until recently, it seemed that the two were independent, without much interaction. [More]
New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma. [More]
FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure). [More]
FDA approves use of Menactra for booster vaccination against meningococcal disease

FDA approves use of Menactra for booster vaccination against meningococcal disease

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age. [More]
New breast cancer vaccine provides evidence of immunotherapy in preventing disease recurrence

New breast cancer vaccine provides evidence of immunotherapy in preventing disease recurrence

A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. [More]
Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International plc announced today that it has introduced the first and only generic 2% topical testosterone gel, an authorized generic of FORTESTA® Gel (testosterone gel) CIII. [More]
Non-invasive delivery of drugs for effective pain relief

Non-invasive delivery of drugs for effective pain relief

Individuals who are squeamish about injections or are looking for a way to let collagen penetrate deeper into the skin may soon have a solution that is faster, more effective and painless. [More]